RESEARCH PAPER

Integrating Artificial Intelligence For Targeted Drug Delivery And Therapeutic Optimization

Muath Khawaji[1*]

[1*] Department Of Computer Science, College Of Engineering And Computer Science, Jazan University, Jazan, Saudi Arabia. Email: m.khawaji@jazanu.edu.sa (Corresponding Author)

Received: *20th Feb, 2026;* ***Revised:*** *4th Mar, 2026;* ***Accepted:*** *25th Mar, 2026;* ***Available Online:*** *10th Apr, 2026*

Abstract

Targeted drug delivery systems are designed to enhance the therapeutic effect of drugs by delivering drugs to the diseased tissues with specificity yet less side effects. The traditional forms of delivery are usually characterized by low levels of specificity, inability to be flexible and inability to control the dosage in the most optimal way. The paper is offering an ai-based system of targeted drug delivery and therapeutic optimization, which entails the machine learning, deep learning and reinforcement learning in a single system. The suggested system takes advantage of the multimodal biomedical data such as genomic, clinical and imaging data to facilitate correct drug targeting, optimum drug dosage selection, and regulated release processes. A feedback system that is a closed loop is included to make changes in the treatment strategies dynamically depending on the response of the patient. Balance between therapeutic efficacy, reduction of toxicity and specificity of targeting are done using mathematical modeling and multi-objective optimization techniques. Empirical evidence shows that the suggested framework has high performance over existing and traditional ai-based methods, with high accuracy, stability of drug concentration, and low level of toxicity. The results point to the opportunities of the ai-based drug delivery systems to develop precision medicine and enhance clinical outcomes.

Keywords: Artificial Intelligence, Targeted Drug Delivery, Precision Medicine, Deep Learning, Drug Optimization, Biomedical Data Analytics.

How To Cite This Article: Khawaji M. Integrating Artificial Intelligence For Targeted Drug Delivery And Therapeutic Optimization. Int J Drug Deliv Technol. 2026;16(28s):529-536. Doi: 10.25258/ijddt.16.28s.64

I. Fundamentals of Targeted Drug Delivery Systems

Targeted drug delivery has become a game-changer in the contemporary therapeutic practices, which seek to improve the efficacy of treatment and reducing the adverse effects of drugs by delivering them specifically to the diseased tissues. Traditional methods of drug delivery usually have a drawback of having systemic distribution, lack of bioavailability and non specific interaction which can result in reduced therapeutic effects and toxicity [1]. This increased complexity in diseases like cancer, neurological and chronic inflammatory conditions further calls on the necessity to develop smart and adaptive drug delivery systems that have the capability to respond to changing biological conditions [2]. The progress in nanotechnology has made it possible to develop advanced drug delivery systems such as liposomes, polymeric nanoparticles, dendrimers and micelles that are capable of releasing drugs in a controlled and localized manner. Although these innovations are present, the problems continue to be the optimization of drug targeting accuracy, predictability of biological responses, and the dynamism in responding to changes in the therapeutic approach [3]. These shortcomings emphasize the necessity of incorporating the data-driven intelligence in the system of drug delivery to enhance accuracy and flexibility. Artificial intelligence (AI) has become one of the most potent facilitators in this regard and provides the possibility to process complex biomedical data, find concealed patterns, and help to make decisions in real-time [4]. Using AI, especially machine learning, deep learning, and reinforcement learning, showed a lot of promise to transform different steps of the drug delivery pipeline. Such techniques facilitate proper prediction of drug-target interactions, optimization of dose regimens as well as customization of treatment plans on patient-specific information [5]. The AI-based models can also utilize multimodal data, such as genomic data, medical imaging, and clinical records, to increase the accuracy of therapeutic

interventions. Intelligent AI in combination with specifically designed drug delivery technologies makes it easier to build intelligent structures that are able to continually learn and evolve thus enhancing therapeutic effects and minimizing off-target side effects [6].



Figure 1. Targeted Drug Delivery Mechanisms Diagram

The intersection of AI and drug delivery can also be used to justify the idea of precision medicine, in which the drug treatment is personalized to the specifics of an individual patient. The AI-enabled systems can dynamically modify the release pattern of drugs by relying on predictive analytics and real-time monitoring, thus providing the optimal therapeutic concentrations in the target site [7]. This is a highly important ability especially in the management of complicated diseases wherein the dosage-response variation in the patient usually constrains the efficacy of standardized therapeutic measures as depicted in figure 1. AI has the potential to speed up the development of drugs by detecting potential therapeutic targets and knowledge of drug delivery to reduce time and cost involved in clinical trials [8]. To make AI models reliable and transparent enough to be adopted by clinics, the accuracy and accountability of AI models should be as high as the healthcare decisions they make. In addition, the large size and quality of biomedical data required is a major obstacle especially where data privacy and data security are paramount issues.

The given work tries to address the combination of artificial intelligence in the targeted drug delivery and therapeutic optimization by offering a thorough analysis of the current approaches, pointing out the gaps in the research and suggesting the AI-based framework of improving the efficiency of drug delivery [9]. The main achievements are the creation of intelligent system architecture, development of optimization strategies to drug targeting, and the analysis of the performance in terms of quantitative metrics and simulation analysis. The project aims to fill the gap between the field of computational intelligence and biomedical uses by providing some insights into the future of AI-enabled precision therapeutics.

II. Role of Artificial Intelligence in Drug Delivery

The use of artificial intelligence has become a game changer in the development of targeted drug delivery systems as it facilitates the use of data to make decisions, predictive modeling and adaptive therapeutic approaches. The growing access to biomedical data, such as genomic sequences, proteomic profiles, medical imaging, and electronic health records have provided AI methods with the opportunity to extract valuable information and streamline the drug delivery processes [10]. In contrast to the classical computational schemes, AI models are able to process high-dimensional and heterogeneous data, which is why they are the most suitable to deal with the complexity of a biological system and personalized medicine [11]. Machine learning algorithms are used to form the basis of drug-target interaction predictions and the best possible delivery paths. The models of supervised learning, including support vector machines, random forests and gradient boosting models, have been popular in classifying drug responses and predicting therapeutic responses [12]. Such models have the ability to examine molecular descriptors, receptor binding affinities and clinical findings to discover trends that can be used to guide the development of targeted therapies. Another type of unsupervised learning such as clustering and dimensionality reduction also contributes to the identification of concealed relationships in biomedical data, making it possible to identify new biomarkers and new therapeutic targets [13].



Figure 2. AI Techniques in Targeted Drug Delivery Optimization

Deep learning has revolutionised the AI-driven drug delivery by allowing automatic feature extraction and learning more representations. Convolutional neural networks are extensively used in medical imaging to detect diseased areas and help delivery of drugs to specific regions, recurrent and transformer-based neural networks are used to analyse time-varying patient and treatment history [14]. Such capabilities are beneficial in improving accuracy in terms of spatial and temporal changes in disease progression. The reinforcement learning offers a mechanism of optimization of drug dosing and delivery techniques as illustrated in figure 2. Learning agents by training with clinical or simulated settings can identify the best policies that enhance therapeutic outcomes with the least side effects [15]. This is especially effective when the treatment is dynamic with a changing response of the patient with time, and the intelligent closed-loop delivery systems are created. The use of artificial intelligence also helps in designing drug carriers. Nanoparticle features observed by predictive models include size, charge, and hydrophobicity, whereas generative models like GANs and VAEs can be used to generate new formulations with a higher targeting efficiency. These methods speed up the process of development and decreases the expenses of experiments.

III. Mathematical Modeling and Optimization Techniques

To develop an AI-based targeted drug delivery system, mathematical modeling is essential as it allows the quantification of drug delivery, interaction with the target site, dosage control, and therapeutic response. The optimization in the proposed framework is presented as a multi-step decision-making problem where factors such as the biological parameters and patient-specific factors in addition to the characteristics of the delivery-system are collectively modeled to optimize the therapeutic benefit and reduce toxicity and off-target exposure. This type of formulation is necessary since delivery of drugs in a targeted manner works under conflicting goals where the goal is to have a high drug concentration in the disease site but too much drug can cause an adverse effect on the body.

$$X = \{x_1, x_2, x_3, \ldots, x_n\}$$

where (x_i) refers to clinical, genomic, imaging or biomarker-based features. This input space is then mapped into a therapeutic decision space by the AI prediction module which is learned.

$$Y = f_{\{\theta\}(X)}$$

where ($f_{\{\theta\}}$) represents the trained AI model that embodies the parameter set (=), and (Y) involves target probability, carrier suitability score and predicted dosage level. This capability is the main decision-making engine that converts patient-specific data to optimized treatment recommendations. In order to represent the concentration of drug at the target site pharmacokinetic representation may be defined as:

$$\mathrm{dtdCt(t)} = \mathrm{kinD(t)} - \mathrm{koutCt(t)}$$

where ($C_{t(t)}$) is the concentration of the drug at the target tissue at time (t), (D(t)) is dose, (kin) is effective delivery rate constant, (kout) is elimination/clearance constant. Such an equation describes how the concentration of a drug in the body varies with time, and is the foundation of the optimization of controlled release. The aim of a desirable system is to ensure that (Ct(t)) lies within a therapeutic window:

$$C_{\{\backslash min\}} \leq C_{t(t)} \leq C_{\{\backslash max\}}$$

The optimization problem can be written in the form of a weighted multi-objective:

$$J = \alpha E - \beta T + \gamma S$$

where (E) representing therapeutic efficacy, (T) representing toxicity and (S) representing targeting specificity and α, (b) and (g) are weighting coefficients. The objective is to maximize (J) within the limits of dosage, carrier and physiological. The optimization problem (in expanded form) is:

$$\max_{\{D,C,R\}};\ J(D, C, R)$$
$$D_{\{\backslash min\}} \leq D \leq D_{\{\backslash max\}}$$
$$R_{\{\backslash min\}} \leq R \leq R_{\{\backslash max\}}$$
$$T(D, C, R) \leq T_{\{\backslash text\{safe\}\}}$$

where (D) is dosage, (C) is carrier configuration, (R) is release rate and (Ttextsafe) is the safety range of toxicity. These limitations are to guarantee clinical feasibility and patient safety. In the case of AI-assisted adaptive control, reinforcement learning can be modeled in the form of a Markov Decision Process with the expressions (S, A, P, R) where (S) is the state of a patient, (A) is an action that can be taken in therapy (e.g., dose change, carrier choice, etc.), (P) is the probability of transitioning between the states.

$$Q(s, a) = b\{E\}\left[\mathrm{sum}_{\{t=0\}_t^{\{\infty\}}\lambda^t r}\right]$$

where (Q(s,a)) is the action-value function, r t is the instantaneous reward, t and (lambda) is the discount factor. The reward functional can be stipulated as in the case of drug delivery.

$$\mathrm{rt} = \eta 1 \cdot \mathrm{Responset} - \eta 2 \cdot \mathrm{Toxicityt} - \eta 3 \cdot \mathrm{OffTargett}$$

This framework allows the model to acquire treatment policies that enhance with time in light of treatment results. The entire optimization process thus combines predictive modeling, pharmacokinetic constraints and adaptive decision making into a single framework. Second, mathematical limits give acceptable therapeutic limits

IV. Proposed AI-Integrated Drug Delivery Framework

A combined system comprising artificial intelligence and targeted drug delivery systems allows the creation of intelligent, adaptive and patient-centric therapeutic systems. The suggested framework is aimed to bring together various steps of the drug delivery pipeline such as data acquisition, target identification, drug design, delivery optimization, and therapeutic monitoring, into a closed and united architecture. The shortcomings of current piecemeal solutions are solved through this integration since it allows on-going learning and real time decision-making. The framework starts with a rich data acquisition layer whereby heterogeneous biomedical data are gathered by various sources including genomic sequencing, protein studies, medical imaging, wearable sensors and electronic health records. Preprocessing and standardization of these data streams is done to provide quality, consistency and interoperability. Relevant biomarkers and disease patterns, and patient specific characteristics that affect therapeutic outcomes are then identified by feature extraction methods. The data that have undergone the processing step are then fed to the AI modeling layer, which uses a mixture of machine learning, deep learning and reinforcement learning methods. Classification and prediction tasks, including determining disease states and predicting drug response are performed by machine learning models. The deep learning designs can be used to recognize patterns in high-dimensional data such as imaging and molecular structures as demonstrated in figure 3. Reinforcement learning creates flexibility in that learning the optimal ways of dosing and delivering drugs via feedback is possible through trial and error. Combination of the models guarantees strong and correct decision-making in various levels of the framework.



Figure 3. Proposed AI-Integrated Drug Delivery Framework Architecture

The framework will have an optimization and decision-making layer, and the insights generated by AI will be converted into actionable therapeutic plans. This stratum is concerned with the optimization of the drug dose, choice of drug carriers and identification of the most efficient way of delivery. Multi-objective optimization algorithms are used to balance conflicting aspects like therapeutic efficacy, toxicity minimization as well as delivery efficiency. These parameters are dynamically adjusted in the system, according to patient-specific conditions and the predicted outcomes. The optimized strategies are applied in the targeted drug delivery layer which entails the application of the advanced drug carriers like nanoparticles, liposomes and stimuli-responsive systems. Such carriers are designed to target the delivery of drugs to the specific location and controlled release is achieved with a low off-target effects. Integration of AI will allow the real-time adjustment of delivery parameters and therefore respond to the changes in the biological environment. An important aspect of the proposed framework is that it has a therapeutic monitoring and feedback layer creating a closed-loop system. The feedback provided by patients such as drug efficacy, toxicity, physiological changes, and others is continuously monitored and introduced into the AI models. Such a feedback mechanism enables the system to revise its forecasts and improve delivery plans, which would be optimized in the long run.

V. Experimental Setup and Dataset Description

The workflow of the experiment is a systematic pipeline of dataset preparation, training of the models, optimization configuration and evaluation in controlled simulation conditions. This article makes use of a multimodal dataset that combines genomic data, medical imaging, clinical records, and pharmacological parameters. Disease specific targets are identified using genomic and biomarker data, whereas spatial localization

of the affected tissues is given by imaging data (CT or MRI). Patient demographics, treatment history and physiological indicators are all a part of clinical datasets, as these are critical to personalized therapy modeling. Because of the sensitivity of medical data in the real world, benchmark datasets and synthetically generated data are made publicly available together, to guarantee reproducibility and compliance with privacy as shown in table 1. Preprocessing of data involves normalization, feature scaling, filling-in of missing values and encoding of the categorical variables.

Table 1: Sample Dataset Description for AI-Based Drug Delivery System

Data Type	Source	Features	Sample Size	Purpose
Genomic Data	Public Bioinformatics Repositories	Gene expression, mutations	5,000 samples	Target identification
Medical Imaging	MRI/CT Datasets	Tumor size, location, intensity	2,000 images	Spatial targeting
Clinical Records	Hospital Databases	Age, history, vitals	3,500 records	Personalized therapy
Pharmacological Data	Drug Databases	Drug properties, toxicity	1,200 entries	Dosage optimization
Synthetic Simulation Data	Generated	PK/PD parameters	4,000 samples	Model training & testing

The dataset will be split into three subsets of training, validation, and testing data as to guarantee the unbiased evaluation of the model, a standard split ratio of 70:15:15 will be used. To integrate into AI models smoothly, feature engineering is carried out to build an integrated representation of patient-specifics as introduced in table 2. Dimensionality reduction algorithms like principal component analysis (PCA) can be used to enhance the efficiency of the computation and minimize noise.

Table 2: Model Parameters and Training Configuration

Parameter	Value	Description
Learning Rate	0.001	Controls model convergence speed
Batch Size	32	Number of samples per iteration
Epochs	100	Total training cycles
Optimizer	Adam	Adaptive gradient optimization
Activation Function	ReLU / Softmax	Non-linear transformation
Discount Factor (RL)	0.9	Future reward weighting

The model training structure includes various AI methods, such as supervised learning to perform classification and regression problems, deep learning to extract features, and reinforcement learning to control adaptive dosage. Python-based models, like TensorFlow and PyTorch, are used to implement models. The grid search and cross-validation are used to set hyperparameters to produce the best performance. Some of the important parameters are the learning rate, batch size, the number of epochs and the model depth. The techniques to avert overfitting are early stopping and regularization. The evaluation protocol will be used to gauge the performance of the system in various criteria. Accuracy, precision, recall and F1-score are used to evaluate classification models whereas mean squared error (MSE) and root mean squared error (RMSE) are used to evaluate regression tasks. Drug delivery performance is evaluated based on the domain specific measurements like efficiency of targeting, stability of drug concentration and rate of reduction in toxicity. Experiments are carried out using simulation to test the behavior of a system under different physiological conditions such as variation in the rate of drug absorption, clearance rate and patient variation.

VI. Performance Evaluation and Results Analysis

The evaluation of the proposed AI-based drug delivery system is carried out based on a set of quantitative measures, analysis through simulations, and comparative benchmarking with the available methods. The goal is to evaluate the capability of the system to enhance the accuracy of targeting, increase the therapeutic efficacy

and decrease the toxicity without sacrificing the computational efficiency and adaptability. The assessment model includes classification, regression and domain specific biomedical performance measures to ascertain a thorough examination as shown in table 3. The integrated approach has a better predictive reliability, especially in determining optimal drug targets and prediction of patient specific responses, compared to the traditional and standalone machine learning models.

Table 3: Performance Comparison of Drug Delivery Models

Model Type	Accuracy	Precision	Recall	F1-Score
Traditional Model	0.72	0.70	0.68	0.69
ML-Based Model	0.81	0.79	0.77	0.78
DL-Based Model	0.87	0.85	0.84	0.85
Proposed AI Model	**0.93**	**0.91**	**0.90**	**0.91**

The findings show that the AI framework suggested is much better in classification with the accuracy being 93, which is about 21% better than the old models. The enhancement is credited to the incorporation of deep learning in extraction of features and reinforcement learning in optimization that is adaptive.



Figure 4. Feature Importance Analysis in AI-Based Drug Delivery Optimization

The proposed system shows a better stability in terms of drug concentration in the therapeutic window with time. The AI-based model uses a controlled release of drugs in contrast to the traditional models as illustrated in figure 4, which have a rapid drop because the release is not controlled.



Figure 5. Cumulative Distribution of Drug Response Outcomes

The plot depicts that the proposed model has a more stable concentration profile which minimizes fluctuations and the risk of toxicity as seen in figure 5. This stability is essential in those treatments that need a controlled dosage e.g. chemotherapy, chronic diseases.



Figure 6. Distribution of Predicted Drug Response Across Patient Samples

Additional analysis involves optimization of efficiency and toxicity whereby the suggested system has a targeting efficiency of about 88% versus 65% with the conventional methods. The effect of optimized dosing and controlled release mechanisms in the reduction of toxicity levels by almost 30% is evident in figure 6. The robustness of the framework is validated by simulation conditions under different physiological conditions, showing similar performance with different patient profiles. The reinforcement learning element allows an ongoing refinement process by refining the decision policies in response to patient response and therefore

provides an improved treatment plan after subsequent cycles.

VII. Comparative Analysis with Existing Methods

A comparative analysis shows the benefits of the suggested AI-based drug delivery system compared to traditional and the currently used AI-based methods. The conventional drug delivery systems are based on passive or active targeting with fixed release profiles and hence lacked adaptability and mediocre therapeutic capabilities. Machine learning-informed approaches are effective at enhancing the prediction of the drug-target interactions but tend to be limited to structured data types and do not offer adaptability in real-time to the extent as shown in table 4. Deep learning methods are more effective in feature extraction and targeting accuracy; although they are generally limited to prediction without the implementation in the delivery control systems.

Table 4: Comparative Benchmarking of Drug Delivery Methods

Method	Technique	Adaptability	Targeting Accuracy	Toxicity Reduction
Conventional	Carrier-based	Low	Moderate	Low
ML-Based	SVM, RF	Moderate	Good	Moderate
DL-Based	CNN, RNN	Moderate	High	Moderate
Proposed Framework	**ML + DL + RL**	**Very High**	**Very High**	**High**

The suggested framework is unique as it is built on the triad of machine learning, deep learning, and reinforcement learning in a closed-loop design. Such integration allows processing multimodal data, optimization of the dosage in real time, and decision-making based on feedback. This leads to a greater targeting accuracy, increased therapeutic efficacy and minimally toxicity of the system in comparison to the methods used today.



Figure 7. Comparative Analysis of Drug Delivery Methods

The findings confirm the suggested strategy has a better performance because of its ability to adapt to the learning process and integrating predictive and optimization elements as depicted in figure 7. It is also more appropriate in the context of precision medicine, as unlike the current models, it constantly optimizes the treatment approaches according to patient response.

VIII. Conclusion

The implementation of AI into the desired drug delivery systems is a significant change in the modern treatment courses. The proposed AI-driven system is able to integrate the predictive models, optimization methods and adaptive feedback solutions to enhance improved delivery of drugs and therapeutic results. The system is capable of determining the drug targets, the drug is optimum dose and the release strategies through multimodal biomedical data to fit the individual profile of patients. The results of the test indicate that the proposed framework is more effective than existing and conventional AI-based solutions in terms of precision in targeting, stability in the drug concentration and low toxicity. The system is also augmented with reinforcement learning, which enables the system to undergo a continuous improvement, since it adjusts to the feedback. This dynamic ability makes sure that therapeutic interventions are still effective despite different physiological conditions, making this framework ideally applied in managing complex and chronic diseases. In terms of the system perspective, the modular architecture has better scalability and flexibility, and can be integrated with other clinical datasets, delivery mechanisms and monitoring systems. The combination of data processing, decision-making, and therapeutic implementation into a closed-loop system allows the framework to be a useful solution to precision medicine. However, such problems as the supply of data,

an explanatory model, and regulatory constraints should be addressed to allow the real clinical implementation.

The explainable AI approaches can be the future of AI in healthcare, as they can be used to improve transparency, personalized simulation via digital twins, and continuous monitoring via real-time wearable sensors. The future of targeted drug delivery systems is likely to be even more efficient and reliable with the development of nanotechnology and smart drug carriers, which are to be optimized by AI.

References

[1] L. Lloyd, "AI for drug discovery," *Nature Reviews Urology*, vol. 21, p. 517, 2024.

[2] V. Kaul, S. Enslin, and S. A. Gross, "History of artificial intelligence in medicine," *Gastrointestinal Endoscopy*, vol. 92, pp. 807–812, 2020.

[3] S. Dara, S. Dhamercherla, S. S. Jadav, C. M. Babu, and M. J. Ahsan, "Machine learning in drug discovery: A review," *Artificial Intelligence Review*, vol. 55, pp. 1947–1999, 2022.

[4] G. Krikorian and E. Torreele, "We cannot win the access to medicines struggle using the same thinking that causes the chronic access crisis," *Health and Human Rights*, vol. 23, pp. 119–127, 2021.

[5] V. P. Chavda, D. Vihol, A. Patel, E. M. Redwan, and V. N. Uversky, "Introduction to bioinformatics, AI, and ML for pharmaceuticals," in *Bioinformatics Tools for Pharmaceutical Drug Product Development*. Hoboken, NJ, USA: John Wiley & Sons, 2023, pp. 1–18.

[6] M. Rudrapal, K. K. Kirboga, M. Abdalla, and S. Maji, "Explainable artificial intelligence-assisted virtual screening and bioinformatics approaches for effective bioactivity prediction of phenolic cyclooxygenase-2 (COX-2) inhibitors using PubChem molecular fingerprints," *Molecular Diversity*, 2024.

[7] I. Kavasidis, E. Lallas, V. C. Gerogiannis, T. Charitou, and A. Karageorgos, "Predictive maintenance in pharmaceutical manufacturing lines using deep transformers," *Procedia Computer Science*, vol. 220, pp. 576–583, 2023.

[8] M. Bagherian, E. Sabeti, K. Wang, M. A. Sartor, Z. Nikolovska-Coleska, and K. Najarian, "Machine learning approaches and databases for prediction of drug–target interaction: A survey paper," *Briefings in Bioinformatics*, vol. 22, pp. 247–269, 2021.

[9] F. Bai, S. Li, and H. Li, "AI enhances drug discovery and development," *National Science Review*, vol. 11, 2024.

[10] A. Hill, J. M. True, and C. H. Jones, "Transforming drug development with synthetic biology and AI," *Trends in Biotechnology*, vol. 42, pp. 1072–1075, 2024.

[11] F. Bray, M. Laversanne, E. Weiderpass, and I. Soerjomataram, "The ever-increasing importance of cancer as a leading cause of premature death worldwide," *Cancer*, vol. 127, pp. 3029–3030, 2021.

[12] Z. Xia, J. Wang, J. Xia, M. Wang, and Z. Cheng, "Inequality in accessibility of proton therapy for cancers and its economic determinants: A cross-sectional study," *Frontiers in Oncology*, vol. 12, 2022.

[13] K. E. Henson, P. McGale, S. C. Darby, M. Parkin, Y. Wang, and C. W. Taylor, "Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries," *International Journal of Cancer*, vol. 147, pp. 1437–1449, 2020.

[14] S. K. Niazi, "The coming of age of AI/ML in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives," *Drug Design, Development and Therapy*, vol. 17, pp. 2691–2725, 2023.

[15] A. Blanco-González, A. Cabezón, A. Seco-González, D. Conde-Torres, P. Antelo-Riveiro, Á. Piñeiro, and R. Garcia-Fandino, "The role of AI in drug discovery: Challenges, opportunities, and strategies," *Pharmaceuticals*, vol. 16, p. 891, 2023.